FDA approves pegfilgrastim biosimilar Udenyca OnBody autoinjector

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

FDA approves pegfilgrastim biosimilar Udenyca OnBody autoinjector

Biosimilares/Novedades | Posted 06/02/2024 0 Post your comment

On 26 December 2023, Coherus BioSciences announced the US Food and Drug Administration’s (FDA) approval of Udenyca OnBody, an on-body injector (OBI) presentation of Udenyca (pegfilgrastim-cbqv), a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim. It serves to stimulate the level of white blood cells (neutrophils). Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy [1]. The originator product is Amgen’s Neulasta. Udenyca was first approved in the US in 2018 [2] and Coherus’ Auto-injector version was approved in early 2023 [3].

Now, Udenyca OnBody is worn directly on the patient’s body and injects Udenyca into the patient. After the drug is administered, the needle automatically retracts, which, can reduce the risk of injury from the needle. The device also has an indicator and status light, as well as an auditory signal that helps patients confirm that Udenyca has been administered.

‘We expect that Udenyca Onbody’s 5-minute injection time and innovative retractable needle mechanism will be well received by cancer patients, their caregivers and doctors,’ said Paul Reider, Coherus’ chief commercial officer.

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: La FDA aprueba el biosimilar de bevacizumab Avzivi

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: La FDA aprueba el biosimilar de bevacizumab Avzivi

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of pegfilgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Feb 6]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-pegfilgrastim
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Feb 6]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-the-us
3. GaBI Online - Generics and Biosimilars Initiative. US and EC approvals for Hyrimoz, US approval for Udenyca autoinjector [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Feb 6]. Available from: www.gabionline.net/biosimilars/news/us-and-ec-approvals-for-hyrimoz-us-approval-for-udenyca-autoinjector

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.